# MoonLake’s nanobody boosts all clinical endpoints in phase 3 psoriatic arthritis trial

> **Newsylist Open Intelligence Dossier** · First detected: 2026-08-10 20:29 UTC · Category: Business · Sources: 5 · Current Velocity: 2.8

## Multi-Source Evidence Table
| Source Outlet | Headline | Published (UTC) | Verification URL |
|---|---|---|---|
| marketscreener.com | MoonLake's psoriatic arthritis drug meets key goals in late-stage trial | 2026-08-10 15:00 | [Source Link](https://news.google.com/rss/articles/CBMiwgFBVV95cUxNZU51Z3lzcS1GUVFUT1BzTnI2RjJfNkhGMDZhcURGRldNbjR6U1lCNjBzQzdnVENqaU9IWF9wbFhmVjkzemtmZUtRVlB4Z0h6T09PeTNlUHpwNmZJVGpyVGg2Skh5aXJsdkZVRnc0dC1pbXdYTktOcjAzb0V4U0ctQlJUcnh2OUNXTC05OHRDcG00YUViYWU4TjZ5UkRrWTNlY0h6NFZtb1N5VU0xRk5taThnRVEyQnl5T3hac2FYTThZdw?oc=5) |
| Dermatology Times | Sonelokimab Meets Primary End Point in Phase 3 Psoriatic Arthritis Trial | 2026-08-10 15:00 | [Source Link](https://news.google.com/rss/articles/CBMirwFBVV95cUxQcGdhR3ZTWTRsWG1RV3k4UU5na2FtREJZUXRqSHFKemFoRFdkQUM1M0pCRGdTaGtJV2xiTzA1b0FoNjM5R3Z1YmprWXVkd3doM3BHYVF1NjBfd1I5a2w4ejlLMnBuYzNUNjdDZTZWRDdyZ1ZqeVV1SXVIZnFXSDZaaE5lTDB4bmh3MF9MSDFfOE15YlRkNkc4T0lqdXI4TXBZc01XanhEbjJNbE43cDk4?oc=5) |
| Kalkine Media | MoonLake Immunotherapeutics Announces Q2 2026 Financial Results with Increased Net Loss and Cash Reserves | 2026-08-10 15:00 | [Source Link](https://news.google.com/rss/articles/CBMi5wFBVV95cUxOVlpjRzJwU1JQTzJTZW1aWmk0amJpVnoyR2k3cnpyWnV2X1ptcTl5aDMzX1lQVFFqbUw0ekI3YTUtYnhBNVp6dG44M2hBak5vV05RMnB4aHl6QUlfUXBJVlQ4VERxUGF3N2lXUE93U2ttN0htRzQ5Z1lCZ0NrbFJYQy1BTnprMlBxeDduNkNiWTdHTnpYQkRsZmM3cWtqMDNac1BCbzMzTmNrWXpHSGVVbFZ6VmZxbkR4WUE1ZEcxTVI1YXAwVDNDZjVWcmNfOXpfVUp5eE44UEpKdWtmTXRvNHBQTWJNdjg?oc=5) |
| FirstWord Pharma | MoonLake touts Phase III PsA data, but investors may have wanted more | 2026-08-10 15:00 | [Source Link](https://news.google.com/rss/articles/CBMiU0FVX3lxTE5XR1I2YnY1WlNTOUtndURTSDJmb1JxNHI1eVhvZTh4NlJVZ3c5ckZzd3F1THRCTUlWc0d2T2JsR2hiS3BXZWNpaXdTRUt2MnhZWnhV?oc=5) |
| Fierce Biotech | MoonLake’s nanobody boosts all clinical endpoints in phase 3 psoriatic arthritis trial | 2026-08-10 15:00 | [Source Link](https://news.google.com/rss/articles/CBMiwgFBVV95cUxPaHFCelFJaUZMQVNHUG9OUkQzTTFVaHA4Y0s1VkJSV3ZYdjRTU1RmNmh1UlJrM044MGQ4Q0NlWXltbnE4ZHpoTkdwa2twM1FtUDNqclhUbzhGeDVXN0cwb1B3ZF9JR0FtR1JaRmFuZ3VERng3cDAycUdrWkxfaUR0V3VnSl85dFZ0LV91S0d6SThSRXBTTlBBbGNaRGI1ajIzQktnWnNoMzhEUlY1bjJFZXlEQ2lIck9fQ1luU3FFX1phQQ?oc=5) |

---
*Canonical Source: https://www.newsylist.com/trend/2026-08-10/moonlake-s-nanobody-boosts-all-clinical-endpoints-in-phase-3-psoriatic*
*Synthesized by Newsylist Open Intelligence Engine under E-E-A-T journalistic standards.*